Keywords: boeh, ingelheim, option, license, prostate, cancer, drug

Boeh Ingelheim Option To License Prostate Cancer Drug

Article | 29 May 1995

Print This

Boehringer Ingelheim has signed an agreement with British Technology Group, granting BI an option to an exclusive license to develop ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in